Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,466.21 -3.09 (-0.06%) Dow
38,966.32 -145.84 (-0.37%) Nasdaq
17,767.15 +49.50 (+0.28%) Bitcoin USD
61,804.20 +230.02 (+0.37%) CMC Crypto 200
1,282.18 -1.60 (-0.12%)
CMPS Nov 2024 10.000 put
| Previous close | 4.1000 |
| Open | 4.1000 |
| Bid | 4.1000 |
| Ask | 4.7000 |
| Strike | 10.00 |
| Expiry date | 2024-11-15 |
| Day's range | 4.1000 - 4.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 28 |
GlobeNewswireCompass Pathways appoints Lori Englebert as Chief Commercial Officer
New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatmentLatest of several key executive team hires, rounding out team to take Compass through phase 3 and beyond LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appoint
- GlobeNewswire
Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
LONDON, June 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference at 7:00 am ET on June 27, 2024. The company will also participate in a panel discussion titled “Commercialization of Novel Compounds in Psychiatry” at 12:00pm ET on June 27, 2024.
Washington PostAfter FDA setback, psychedelic drugmakers distance themselves from a pioneer
CORRECTION: A previous version of this article misstated the position of Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies. Doblin has said MDMA could help reduce the world’s trauma, not eliminate it. Originally moved June 8. - - - Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. Developers of mind-bending drugs for medical use are distancing themselves from the first company to seek regulatory approval
